. 2023 Jun 22;14:3706. doi: 10.1038/s41467-023-39328-1

Table 2.

Tau PTMs

Kruskal–Wallis FDR adjusted P value		Wilcoxon group pairwise comparison
Kruskal–Wallis FDR adjusted P value		AD vs CTL	CBD vs CTL	FTLD 4 R vs CTL	FTLD 3 R vs CTL	PiD vs CTL	AD vs CBD	AD vs FTLD 4 R	AD vs FTLD 3 R	AD vs PiD	CBD vs FTLD 4 R	CBD vs FTLD 3 R	CBD vs PiD	FTLD3R vs FTLD4R	FTLD4R vs PiD	FTLD3R vs PiD
Sarkosyl-insoluble tau (aggregates)
Ub-K311	2E-04	++					++	++	++	++
P-S262	1E-03	++					++	+	++	++		+
P-T217	4E-03	++	++					+	++	++		++	+
P-S396	4E-03	+					+		+	+
P-S324	4E-03	++	++	+	+			+	++	++		++	+
P-T231 + P-S238	8E-03	++	++	+				++	++	++	+	++	+
Ub-K369	9E-03		+				–				+	++	+
Ub-K343	9E-03	+	++						+			++	+
Ac-K353	2E-02	+							+	+
Ac-K311	2E-02	+			+		+	+				-
Ac-K369	4E-02	+								+
P-T231	4E-02	++	++	+	+	+		+	+	+
Me-K331	4E-02				+							-
Sarkosyl-soluble tau
Ub-K254	4E-04	++	++					++	+++	++	+	++	++
Ub-K311	4E-04	++					++	++	++	++
Ub-K259	4E-04	++	+			-		+	+++	++		++	++		+
P-S262	4E-04		++	+	++		- - -	-	- - -
P-S262 + Ub-K267	4E-04	++					++	+	++	++
Ub-K317	4E-04	++					+	++	++	++
Ub-K267	4E-04	++	++	+		+	+		++	++		++	++
Ub-K369	1E-03		++				- - -				+	++	++
Ub-K343	1E-02		+				- -		+		+	++	++	-		-
P-T231 + P-S237 + P-S238	2E-02	++	++	+	++	+		+			+
P-S396 + P-S400 + P-S404	2E-02	++	++	+	++						+		+
Ac-K311	3E-02	+			+	+	+					-	-	+	-
P-S184 + P-S185	3E-02	++		+	+	+	+
P-S113	4E-02	+		+	++				-
P-T212 + P-T217	4E-02	++	++		++
Me-K180	4E-02	++	+	+	+	+
P-S396 + P-S400	4E-02	+	+	+	++	+
P-S185 + P-S191	5E-02	+			++	+
P-T231 + P-S238	5E-02	++	+		++

Only pathology-related PTMs are displayed, i.e. the ones whose abundances (AUC) were significantly higher in a disease group than in CTL (FDR adjusted Kruskal–Wallis’s P < 0.05). The table shows the result of the post-hoc Wilcoxon’s pairwise group comparisons on PTMs (^+/−P < 0.05; ^{+ +/- -}P < 0.005; ^{+ + +/− − −}P < 0.0005). All statistical tests were two-tailed. Source data are provided as a Source Data file (see sheet 5 for the exact P values). Plus sign and Minus sign represent either a significant increase or significant decrease, respectively, in the condition at the top position of the panel heading. PTMs with p-values in bold font are those specific for AD (insoluble tau Ub-K311 and P-S262; soluble tau Ub-K311, Ub-K317 and P-S262+Ub-K267), for 4R-tauopathies (insoluble tau Ub-K369; soluble tau Ub-K343 and Ub-K369) and for 3R-tauopathies (insoluble tau Ac-K311 and Me-K331; soluble tau Ac-K311). PTMs are numbered according the full-length (2N4R) tau protein. AD Alzheimer’s disease (n = 15), CBD corticobasal degeneration (n = 5), PiD Pick’s disease (n = 5), FTLD frontotemporal lobe degeneration (n = 10, including FTLD-4R, n = 4 and FTLD-3R, n = 6); control subjects, CTL (n = 5).